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Abstract
Background: Cytokine administration is a potential therapy for acute liver failure by reducing inflammatory responses and
favour hepatocyte regeneration. The aim of this study was to evaluate the role of interleukin-1 receptor antagonist (IL-1ra)
during liver regeneration and to study the effect of a recombinant human IL-1ra on liver regeneration.
Methods: We performed 70%-hepatectomy in wild type (WT) mice, IL-1ra knock-out (KO) mice and in WT mice treated by
anakinra. We analyzed liver regeneration at regular intervals by measuring the blood levels of cytokines, the hepatocyte
proliferation by bromodeoxyuridin (BrdU) incorporation, proliferating cell nuclear antigen (PCNA) and Cyclin D1 expression.
The effect of anakinra on hepatocyte proliferation was also tested in vitro using human hepatocytes.
Results: At 24h and at 48h after hepatectomy, IL-1ra KO mice had significantly higher levels of pro-inflammatory cytokines
(IL-6, IL-1b and MCP-1) and a reduced and delayed hepatocyte proliferation measured by BrdU incorporation, PCNA and
Cyclin D1 protein levels, when compared to WT mice. IGFBP-1 and C/EBPb expression was significantly decreased in IL-1ra
KO compared to WT mice. WT mice treated with anakinra showed significantly decreased levels of IL-6 and significantly
higher hepatocyte proliferation at 24h compared to untreated WT mice. In vitro, primary human hepatocytes treated with
anakinra showed significantly higher proliferation at 24h compared to hepatocytes without treatment.
Conclusion: IL1ra modulates the early phase of liver regeneration by decreasing the inflammatory stress and accelerating
the entry of hepatocytes in proliferation. IL1ra might be a therapeutic target to improve hepatocyte proliferation.
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Introduction
Acute liver failure (ALF) occurs when the extent of hepatocyte
death exceeds the liver’s regenerative capacity. Furthermore, the
regeneration of native liver may be impaired by accumulation of
various toxic substances such as ammonia or nitric acid [1]. This
clinical devastating syndrome is associated with a significant
morbidity and mortality reaching 80%. Liver transplantation is
currently the only effective therapy for those patients who are
unlikely to recover withstandard care. However, shortage of human
organ donors limits the number of possible transplantations and
additional approaches are crucial to reduce the waiting list [2].
The administration of specific drugs or factors that are able to
initiate and accelerate hepatocyte proliferation has been suggested
as strategy for the treatment of acute liver failure [3]. Thus, the
improvement of liver regeneration by cytokine therapy is a
potential solution to increase the number of patients in whom the
native liver regenerates sufficiently to resume normal function.
Among the many cytokine candidates to improve liver
regeneration, the cytokine IL-1 receptor antagonist (IL-1ra) has
not yet been studied and direct evidence for a role of IL-1ra in
liver regeneration has not been clearly reported [4,5].
IL-1ra is a member of the IL-1 family and is produced by
hepatocytes as an acute-phase protein [6,7]. This cytokine has a
naturally anti-inflammatory effect by binding and blocking
competitively IL-1 receptor, i.e. preventing binding and intracel-
lular signal transduction of IL-1a and IL-1b. The production of
IL-1ra is upregulated by IL-1b, IL-4 and HGF. In the past few
years, IL-1ra has attracted clinical attention because its serum
levels are elevated in diverse human pathologies as infectious
diseases, neoplasic diseases and liver diseases [8].
Recent studies have demonstrated that the activation of IL-1b
signalling results in decrease of hepatocyte proliferation in vitro and
in vivo and that its inhibition induces an improvement of mitogenic
rate of hepatocyte during liver regeneration [9,10,11].
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and exhibits minimal variation [12]. Sekiyama et al. showed that in
patients with fulminant hepatic failure a significantly reduced ratio
of IL-1ra to IL-1 beta (IL-1ra/IL-1b) was observed in patients who
subsequently died compared with subjects who survived [13]. In a
rat model of fulminant hepatic failure induced by D-galactosamine,
Shinoda et al. have shown that animal survival was significantly
improved in animals treated with IL-1ra [14,15]. Recently,
overexpression or administration of IL-1ra in animal models has
been shown to be protective in different liver injury such as hepatic
ischemia-reperfusion injury and hepatitis [16,17,18].
Currently, a non glycosylated recombinant human IL-1ra
(anakinra), is available for clinical use. As the endogenous IL-
1ra, this drug blocks the effect of IL-1b and it is used to treat pain
and swelling of patients with rheumatoid arthritis [19].
The aims of this study were first to evaluate the role of IL-1ra in
liver regeneration in vivo using knock-out mice in which the gene
coding for IL-1ra has been deleted and second to analyse the effect
of anakinra (the non glycosylated recombinant human IL-1ra)
administration on liver regeneration in wild type mice after 70%-
hepatectomy and on isolated human hepatocytes in vitro.
Materials and Methods
Animals
10 to 12 week-old male wild-type (WT) DBA1 mice (Charles
River Laboratories,France),andIL-1raknock-out(KO)DBA1mice
weighing 20 to 25g were used. IL-1ra KO breeding was performed
from animals previously described [20]. Animals were maintained in
conventional housing facilities at the Geneva University Medical
School. This study was conducted under experimental protocols
approved by the ethical committee of the Geneva University
Medical School and by Geneva veterinary authorities.
Induction of liver regeneration
Regeneration of the native liver was induced by performing a
70%-hepatectomy. Briefly, under general anaesthesia, a median
laparotomy was performed. The left lateral and the median lobe
were removed as previously described by Mitchell et al. [21]. In
sham operated mice, hepatectomy was not performed.
Experimental groups
70%-hepatectomy was performed in four different groups of
DBA1 mice:
(I) WT DBA1 mice, n=6
(II) IL-1ra KO DBA1 mice n=5
(III) WT DBA1 mice treated with intraperitoneal (i.p.)
injection of anakinra (5mg/kg/day) (KineretH, Amgen
Europe B.V, Breda, Netherlands) n=5
(IV) WT DBA1 mice treated with i.p. injection of anakinra
(50mg/kg/day) n=5
Two groups contained sham operated DBA1 mice:
(I) WT DBA1 mice treated with i.p. injection of anakinra
(5mg/kg/day) n=5
(II) WT DBA1 mice treated with i.p. injection of anakinra
(50mg/kg/day) n=5
Measurement of cytokines
Blood levels of IL-1ra, IL-1b, TNF-a and TGF-b1 (R&D
system, Minneapolis, USA) and HGF (Institute of Immunology,
Japan) were analyzed by enzyme-linked immunosorbent assay
(ELISA), following the manufacturer’s instructions. IL-6, MCP-1
were measured using a cytometric bead array (CBA) mouse
inflammation kit (BD Biosciences, New Jersey, USA) and analyzed
with a BD FACSArray Bioanalyzer (BD Biosciences), following the
manufacturer’s instructions. The CBA data were analyzed with
BD
TM CBA Software (BD Biosciences). The cytokines were
measured from peripheral blood at 4 h, 24 h, 48 h, 72 h, 5 days
and 7 days after hepatectomy.
Measurement of alanine aminotransferase (ALT)
ALT was analyzed on peripheral blood of mice treated with
anakinra (n=3) and with no treatement (n =3) by the clinical
chemistry unit of University Hospital Geneva using DxC 800
system (Beckman Coulter Inc), following the manufacturer’s
instructions.
Bromodeoxyuridine (BrdU) incorporation
Hepatocyte proliferation was evaluated by Bromodeoxyuridine
(BrdU) incorporation at 24 h, 48 h, 72 h, 5 days and 7 days after
hepatectomy. BrdU (200mg/kg) was given i.p. 2 h before tissue
sampling [22]. Immediately after sacrifice, liver samples were fixed
in 10% buffered and formalin and paraffin embedded. Sections of
5 mm were cut. BrdU incorporation in hepatocyte nuclei was
assessed by immunohistochemistry using Zymed BrdU STAIN-
ING Kit (Zymed Laboratories, San Francisco, CA, USA)
following the manufacturer’s instructions. The proliferation index
of BrdU-stained tissue was determined at 200x magnification and
labelled nuclei were counted in 5 randomly chosen fields, which
approximate 1000 cells per section. Data were expressed as the
percentage of BrdU-stained hepatocytes per total number of
hepatocytes.
Western blot analysis
Liver biopsies were removed at 4 h, 24 h, 48 h, 72 h, 5 days
and 7 days after partial hepatectomy and frozen at 280uC until
protein extracts were prepared by homogenization in a lysis buffer
(0.1 M Tris-HCl buffer, pH 7.4, supplemented with 5 mM EDTA
and 5% SDS) containing complete protease inhibitors cocktail
(Roche, Basel, Switzerland) and phosphatase inhibitor sodium
orthovanadate (1 mM). After a 20 min centrifugation at 14 000g at
4uC, the supernatant was collected, protein concentration of the
protein extracts was determined using the Bio-Rad protein assay
kit (Biorad, ville, pays) and finally samples were stored at -20uC
until western blot analyses. 30 mg of total liver proteins were
separated by electropohoresis in a 12% sodium dodecyl sulphate
(Invitrogen, Taastrup, Denmark) polyacrylamide gel. Proteins
were transferred onto polyvinylamide fluoride membranes (Hy-
bond-P, GE Healthcare, Little Chalfont, United Kingdom).
Membranes were blocked for 1 h at room temperature in a
blocking buffer (Tris-HCl (pH 7.6) buffer containing 150 mmol/l
NaCl, 0.1% Tween-20 and 5% non-fat dry milk). The membranes
were then incubated overnight at 4uC with one of the following
antibodies diluted in the blocking buffer: for PCNA, mouse
monoclonal antibody clone: PC10 (Signet Laboratories, Inc,
Dedham, MA, USA) diluted 1:500; for Cyclin D1, mouse
monoclonal antibody diluted 1:500 (Santa Cruz Biotechnology,
Inc., Heidelberg, Germany). After rinsing in TBS-Tween, the
immunoblots were incubated for 1 h at room temperature with a
goat anti-rabbit or anti-mouse secondary antibody (Hercules, CA,
USA), whichever appropriate, conjugated to horseradish peroxi-
dase and diluted 1:6000 in the blocking buffer.
Finally, membranes were developed by enhanced chemilumi-
nescence detection kit (Amersham Pharmacia Biotech, Piscataway,
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Primers Forward Reverse
C/EBPa 59 CCTGAGAGCTCCTTGGTCA-39 59-GAAACCATCCTCTGGGTC-TC-39
C/EBPb:5 9-ACGACTTCCTCTCCGACCT-39 59-GAGGCTCACGTAACCGTAGTC-39
C-myc 59-AGGCCCCCAAGGTAGTGATC-39 59-GTGCTCGTCTGCTTGAATGG-39
Bclx 59- CAGACACTGACCGTCCACTCA-39 59- GCAATGGTGGCTGAAGAGAGA-39
PPARa 59- TGCAAACTTGGACTTGAACG-39 59- AGGAGGACAGCATCGTGAAG-39
IGFBP-1 59- ATCTGCCAAACTGCAACAAG-39 59-GACCCAGGGATTTTCTTTC-39
C/EBP a= CAAT enhancer binding protein a, C/EBP b= CAAT enhancer binding protein b, IGFBP-1=Insulin-like growth factor binding protein 1, peroxisome
proliferator-activated receptor-a.
doi:10.1371/journal.pone.0025442.t001
Figure 1. Evaluation of liver regeneration in IL-1ra ko mice and in WT mice after 70% hepatectomy. The evaluation of hepatocyte
proliferation on native liver tissue was performed by analyzing BrdU incorporation by immunohistochemistry and by analyzing PCNA expression by
western blot analysis at 24 h, 48 h, 72 h, 5 days and 7 days after 70% hepatectomy in WT mice and IL-1ra KO mice. (A) BrdU incorporation was
significantly higher in WT mice compared to IL-1ra KO mice at 24 h and 48 h after 70% hepatectomy. The proliferation index of BrdU-stained tissue
was determined at 200x magnification and labelled nuclei were counted in 5 randomly chosen fields, which approximate 1000 cells per section. Data
were expressed as the percentage of BrdU-stained hepatocytes per total number of hepatocytes. Positive hepatocytes for BrdU incorporation are
stained in brown. (Original magnification x200). (B) For WT mice, PCNA expression peaked at 48 h, in contrast for IL-1ra KO mice, the PCNA expression
peaked at 72 h. The results are shown as a ratio of PCNA to actin expression. The quantification of signals of PCNA and actin are performed by
densitometry. Scale bars = 50 mm. * = Statistical significance p,0.05. D=day, WT=wild type, KO=knock-out, PCNA=proliferating cell nuclear
antigen.
doi:10.1371/journal.pone.0025442.g001
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of loaded proteins was controlled by probing the same membranes
with a rabbit polyclonal antibody directed against b-actin diluted
1/250. Densitometric quantification of each band was determined
using Quantity One software (PDI, Inc., Huntington Station, NY)
and normalized by comparison with expression of b-actin in the
re-probed blot.
Analysis of Gene Expression by Real-time Polymerase
Chain Reaction
Total RNA was extracted from liver samples harvested from
WT DBA1 and IL-1ra KO DBA1 mice at 4 h, 24 h, 48 h, and
72 h after partial hepatectomy by Qiagen RNeasy Midi kit
(Qiagen, San Diego, USA) according to manufacturer’s instruc-
tions. cDNA was synthesized from 0.5 mg of total RNA using
PrimeScript RT reagent Kit (Takara Bio Inc, Saint-Germain-en-
Laye, France) following suppliers instructions.
For quantitative PCR, amplification of genes was performed
from 2ng cDNA and 300 nM of forward and reverse oligonucle-
otides using the Power SYBR Green PCR Master Mix (Applied
Biosystems Inc, California, USA) and a SDS 7900 HT machine
(Applied Biosystems Inc). Oligonucleotides were obtained from
Invitrogen. The efficiency of each design was tested with serial
dilutions of cDNA. Oligonucleotides amplicons sequences are
described in Table 1. PCR were performed with the following
parameters: 50uC for two minutes, 95uC for ten minutes, and 45
cycles of 95uC 15 secondes260uC one minute. Each reaction was
performed in three replicates on 384-well plate. Raw Ct values
obtained with SDS 2.2 (Applied Biosystems Inc) were imported in
Excel and normalisation factor and fold changes were calculated
using the GeNorm method [23]. Control genes used for
normalization are rps9, eef1a1, Srp72, Gak. These genes were
selected using Genorm method. Srp72 and Gak are the most
stable genes in the liver according to genevestigator (https://www.
genevestigator.com).
Isolation of Human Hepatocytes
Human hepatocytes were obtained from surgical liver biopsies
of patients undergoing segmental hepatectomies. The protocol for
the human studies was approved by the institutional ethics
committee of the Department of Surgery and informed consent
was obtained from the patients. At the start of the intervention, a
wedge of macroscopically normal tissue (15 to 30 g) located within
the part of the liver to be resected was excised, immersed in ice-
cold phosphate buffered saline.
Human hepatocytes isolations were performed using a two-step
collagenase perfusion method as previously described [24,25].
Hepatocyte viability was determined by trypan blue exclusion and
cells were cultured in DMEM/F12 medium (Invitrogen, Basel,
Switzerland) containing 2% Foetal bovine serum (Invitrogen),
1610
26 mol/l dexamethasone (Sigma-Aldrich GmbH, Basel, Swit-
zerland), 1610
28 mol/l 3, 39-triiodo-L-thyronine, 1610
28 mol/l
human insulin (Huminsulin, Lilly France S.A.S, Strasbourg, France),





5 primary human hepatocytes were seeded in 35mm
Tissue Culture dish (Primaria Easy grip, Becton Dickinson, Le
Pont de Claix, France) and incubated at 37uC for 3 days.
To analyze the effect of anakinra on primary human
hepatocytes proliferation in vitro, we treated primary hepatocytes
with anakinra (KineretH) at various doses (10 mg/ml and 100 mg/
ml) added to culture medium at 0h for 72h after hepatocyte
isolation. After isolation, primary human hepatocytes were
cultured for 24h before the beginning of treatment with anakinra.
After 24h, 48h and 72h, protein extracts were prepared by
scrapping primary hepatocytes with lysis buffer (described above)
containing complete protease inhibitors cocktail (Roche, Basel,
Switzerland) and phosphatase inhibitor and stored at 220uC until
assessment of PCNA protein level expression by western blot
analysis.
Cell viability
To study the cell viability, we performed a crystal violet assay.
Human hepatocytes were first seeded at 100,000 cells/well in
500 ml culture medium in 24-well plates and allowed to attach for
24h before anakinra treatment. Cell viability was then determined
by crystal violet staining (Sigma, St. Louis, MO). For this assay,
human hepatocytes were seeded at a density of 100.000 cells/well
in 24-well plates in medium containing 2% FBS, with or without
adjunction of anakinra at 10 (n=3) and 100 microgr/ml (n=3) for
24h and viability was tested at 24, 48 and 72h.
After incubation, the cells were fixed with 10% formalin during
10 min. at room temperature and stained for 30 min. at 37uC with
0.1% crystal violet (Sigma). Then, wells were washed with PBS
three times and the dye was eluted under shaking with 500 mlo f
10% acetic acid for 15 min. at room temperature. Supernatants
were transferred into a 96-well plates and absorbance of each well
was measured at 570 nm using a microplate reader.
Statistical analysis
Data analysis results are presented as means 6 SEM. For in vitro
studies, statistical differences among three or more groups were
examined by Mann-Whitney U test. For in vivo studies, differences
between two groups were examined for statistical significance
using the Kruskal-Wallis Anova test. Quantitative variation was
considered significant at p-value inferior to 0.05. Statistical
analysis was performed using STATISTICA (STATISTICA 5.5
Software for Windows, Statsoft Inc, Tulsa, OK).
Results
Analysis of liver regeneration after a 70%-hepatectomy in
WT and IL-1ra KO mice
Extent of liver regeneration. We analysed hepatocyte
proliferation in native liver tissue of WT and IL-1ra KO mice
after hepatectomy by immunohistochemistry on liver sections
analyzing BrdU incorporation and by western blotting detecting
PCNA expression at 24 h, 48 h, 72 h, 5 days and 7 days.
As shown in figure 1A, BrdU incorporation was increased in
both WT and IL-1ra KO mice at 24 h after hepatectomy and
reached maximal levels at 48 h. BrdU incorporation was
significantly lower in IL-1ra KO mice compared to WT mice at
24 h (2% vs 5%, respectively) and 48 h (14% vs 32%, respectively)
after 70% hepatectomy and return to similar levels at 72 h, and 7
days.
Western blot analysing PCNA expression (Figure 1B) increased
at 24 h after hepatectomy in WT and in IL-1ra KO mice but was
also significantly lower in IL-1ra KO mice at 48 h compared to
WT mice (1.82 arbitrary unit (a. u.) 60.53 vs 0.4060.33,
respectively) confirming the results obtained by BrdU incorpora-
tion. Maximal PCNA expression (1.82 a.u.) was observed in WT
mice 48 h after hepatectomy while, in IL-1ra KO mice, maximal
PCNA expression (1.33 a.u.) was measured 72 h after hepatecto-
my (Figure 1B).
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were analyzed by ELISA. IL-6, MCP-1 were measured by a cytometric bead array mouse inflammation kit. These cytokines were measured on peripheral blood
of WT mice and IL-1ra KO mice at 4 h, 24 h, 48 h, 72h, 5 days and 7 days after partial hepatectomy. A) The level of IL-1ra in WT mice showed a significant
increase between 4 h and 48 h. As expected, in IL-1ra KO mice, IL-1ra was not detectable; B-D) the levels of IL-1b, IL-6 and MCP-1 were significantly higher in
IL-1ra KO mice than in WT mice with a significant difference at 4 h post-hepatectomy; E-F) there were no differences in the levels of TNFa and HGF between
the two groups of mice; * = Statistical significance p,0.05. D = day IL-1ra = Interleukin-1 receptor antagonist, IL-1b = Interleukin-1b, IL-6 = Interleukin-6,
MCP-1 = monocyte chemotactic protein-1, TNFa = Tumor necrosis factor- a, HGF = Hepatocyte growth factor, WT = wild type, KO = knock-out.
doi:10.1371/journal.pone.0025442.g002
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1ra, IL-1b, TNF-a, TGF-b1, HGF, IL-6 and MCP-1 levels were
measured in serum of WT and IL-1ra KO mice at 4 h, 24 h, 48 h,
72 h, 5 days and 7 days after partial hepatectomy. In WT mice, IL-
1ra level increased significantly between 4 and 48 h after
hepatectomy (33612 pg/ml at 0 h, 252692 pg/ml at 4 h,
3906147 pg/ml at 48 h) (Figure 2A). After 48 h, the IL-1ra level
progressively decreased until 7 days but was still remained higher
than before hepatectomy. As expected, IL-1ra KO mice did not
produce IL-1ra (Figure 2A). IL-1b levels were higher in IL-1ra KO
than in WT mice at all time points with significant differences at 4 h
(383644 pg/ml vs 125626 pg/ml, respectively) and at 7 days
(328689 pg/ml vs 14069 pg/ml, respectively) after hepatectomy
(Figure 2B). IL-6 level increased at 4 h post-hepatectomy in WT
and IL-1ra KO mice. This increased secretion was significantly
higher in IL-1ra KO than in WT mice (11646273 pg/ml vs
38626680 pg/ml, respectively) (Figure 2C). A significant increase
of MCP-1 level was observed in IL-1ra KO mice at 4 h and at 24 h
versus WT mice (629.96109 pg/ml vs 109627 pg/ml at 4h and
268669.2 pg/ml vs 24.78 respectively) after hepatectomy
(Figure 2D). TNF-a and HGF levels increased 4 h after
hepatectomy in WT and IL-1ra KO mice (Figure 2E-F). There
were no differences in the levels of TNF-a and HGF between the
two groups of mice. These data suggest that IL-1 signalling
pathways may regulate the expression of IL-6 and MCP-1 in the
early phase of liver regeneration after hepatectomy.
Analysis of cell cycle protein expression. To determine
whether the delay and decrease of hepatocyte proliferation
observed in IL-1ra KO mice could be a consequence of
alterations in the G1/S checkpoint of the cell cycle, cyclin D1
expression was analyzed by western blotting at 24 h, 48 h, 72 h
and 7 days after 70% hepatectomy in WT and IL-1ra KO mice.
Cyclin D1 was recently identified as the most reliable marker for
cell cycle (G1 phase) in hepatocytes [26].
As shown in figure 3A and 3B, Cyclin D1 expression
increased significantly between 0 to 48 h after 70% hepatecto-
my in WT mice (0.0560.4 a.u. at 0 h, 0.3660.13 a.u. at 24 h,
0.7260.09 a.u. at 48h and 0.4760.2 a.u. at 72h). In IL-1ra KO
mice, a significant increase of expression was observed later,
b e t w e e n2 4a n d7 2h( 0 . 0 4 60.02 a.u. at 0 h, 0.1160.01a.u. at
24 h, 0.3560.11 a.u. at 48 h and 0.48 a.u. at 72 h). These
results indicate a delayed cyclin D1 expression in IL-1 ra KO
mice after partial hepatectomy. These results indicate a delayed
cyclin D1 expression in IL-1 ra KO mice after partial
hepatectomy.
Analysis of genes implicated in liver regeneration. Ex-
pression of genes implicated in liver regeneration (Bcl-xl, CEBPa,
C/EBP b, c-myc, IGFBP-1 and PPARa) was analyzed by real-
time polymerase chain reaction at 0 h, 4 h, 24 h, 48 h, and 72 h
after partial hepatectomy (Figure 4).
Expression levels of Bcl-xl, C-myc and PPARa were not
modified in WT and IL-1ra KO mice (Figure 4 A, C, E). The
expression of Bcl-xl at 4 h and c-myc at 24 h tended to be lower in
IL-1ra KO mice compared to WT mice, but the difference did not
reach statistical significance (Figure 4 A and C). Expression of C/
EBPa decreased after partial hepatectomy in a similar way for IL-
1ra KO and WT mice (Figure 4D). IGFBP-1 and C/EBPb
expression increased at 4 h after hepatectomy and were
significantly lower in IL-1ra KO mice compared to WT mice
(fold increase 15.3 vs 59.1. for IGFBP-1 and 2.48 vs 7.5. for C/
EBPb, respectively) (Figure 4B and 4F).
Analysis of liver regeneration after 70% hepatectomy in
WT mice treated by anakinra
In order to investigate whether the treatment of anakinra has a
positive effect on hepatocyte proliferation after injury, we
performed a 70% hepatectomy in WT mice treated with anakinra
at two doses (5mg/kg/day and 50mg/kg/day).
Figure 3. Analysis of Cyclin D1 expression in IL-1ra KO mice and in WT at early time points after hepatectomy. Expression of cell cycle
protein Cyclin D1 was analysed by western blot analysis on native liver tissue recovered at 24 h, 48 h, 72 h, 5 days and 7 days after 70% hepatectomy
in WT and IL-1ra KO mice. A) Western blot of cyclin D1. The quantification of bands of Cyclin D1 and actin are performed by densitometry. B) Cyclin
D1 is significantly higher in WT mice compared to IL-1ra KO mice at 24 h and 48 h after 70% hepatectomy. Cyclin D1 increased significantly at 24 h in
WT mice, and in IL-1ra KO mice at 48 h after hepatectomy. The results are expressed as a ratio of Cyclin D1 expression by actin expression. The
quantification of bands of Cyclin D1 and actin are performed by densitometry. * = Statistical significance p,0.05. D = day, WT = wild type, KO =
knock-out .
doi:10.1371/journal.pone.0025442.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25442Figure 4. Expression of genes involved in liver regeneration. We analysed the expression of various genes implicated in liver regeneration (Bcl-xl,
C/EBPa,C/ EB P b,c-myc,IGFBP-1andPPARa)byreal-timepolymerasechainreactionatvarioustimepoints0 h,4 h,24 h,48 h,72 hpost-hepatectomy.(A–
H)Our results demonstratethatIGFBP-1 and C/EBPb expressionwas significantlyincreased at4 h inWTmicecompared toIL-1raKO(fold increase59.1vs.
15.3 for IGFBP-1 and 7.5 vs. 2.48 for C/EBPb, respectively). Bcl-xl and c-myc expression was higher in WT mice but did not reach statistical significance.
Expression level of C/EBPa and PPARa was similar. The fold increase was calculated for various time points and time 0 (0h) in control animals was used for
normalization. * = Statistical significance p,0.05. WT = wild type, KO=knock-out, C/EBPa = CAAT enhancer binding protein a,C / E B P b = CAAT
enhancer binding protein b, IGFBP-1= Insulin-like growth factor binding protein 1, PPARa = Peroxisome proliferator-activated receptor alpha.
doi:10.1371/journal.pone.0025442.g004
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untreated and anakinra treated (5mg/kg/d and 50mg/kg/d for 4
days) WT mice was evaluated by BrdU incorporation (analyzed by
immunohistochemistry) and by PCNA expression (analyzed by
western blotting) at 24 h, 48 h, 72 h, 5 days and 7 days after 70%
hepatectomy. BrdU incorporation was significantly higher in WT
mice treated with anakinra at 50mg/kg compared to untreated mice
at 24 h (8.04% vs 3.63% at 24 h, respectively) (Figure 5). BrdU
incorporation wasnot different between the untreated and anakinra-
treated mice at later time points (48 h and 72 h) after partial
hepatectomy. As a control, the treatment of anakinra alone had no
effect on BrdU incorporation in sham-operated mice (Figure 5A).
Similary, PCNA expression level was significantly higher in WT
mice treated with anakinra at 50mg/kg/d compared to untreated
WT mice at 24 h after 70% hepatectomy (0.4060.09 a.u. vs
0.1260.02 a.u., respectively) (Figure 5). At the same time point,
treatment of mice with a lower dose of anakinra (5mg/kg/d) had
no effect on the PCNA expression level. At 48 h and 72 h after
hepatectomy, PCNA expression was similar between untreated
and treated mice at low and high doses of anakinra. Finally, the
treatment of anakinra alone had no effect on PCNA expression in
sham-operated mice (Figure 5B). These data show that treatment
with non-glycosylated recombinant human IL-1ra, anakinra at a
dosis of 50 mg/kg/d, leads to an increased hepatocyte prolifer-
ation 24 h after partial hepatectomy.
Cytokines levels implicated in liver regeneration. IL-6,
MCP-1 and IL-1b levels were measured from peripheral blood of
WT mice either untreated or treated with two doses of anakinra
(5mg/kg/d and 50mg/kg/d for 4 days) at 4 h, 24 h, 48 h, and
72 h, after partial hepatectomy. At 4 h post-hepatectomy, IL-6
levels were significantly reduced in WT mice treated with low
and high doses of anakinra compared to untreated WT
mice (149616 pg/ml, 169624 pg/ml vs 11646273 pg/ml
respectively treated with 5mg/kg/d and 50mg/kg/d anakinra vs
Figure 5. Evaluation of liver regeneration in mice treated by anakinra at 5mg/kg/d and at 50mg/kg/d after 70% hepatectomy. The
evaluation of hepatocyte proliferation on native liver tissue was performed by analyzing BrdU incorporation by immunohistochemistry and by
analyzing PCNA expression by western blot analysis at 24 h, 48 h, 72 h, 5 days and 7 days after 70% hepatectomy in untreated WT mice and groups
of WT mice treated with anakinra (5mg/kg/d and 50mg/kg/d for 4 days). (A) BrdU incorporation was significantly higher in WT mice treated with
anakinra at 50mg/kg compared to untreated mice at 24 h. At a 10 times lower dose (5mg/kg/d), BRDU incorporation was not different at 24 h in
treated and untreated WT mice. At 48 h, the PCNA expression level was similar in all three groups of mice. The proliferation index of BrdU-stained
tissue was determined at 200x magnification and labelled nuclei were counted in 5 randomly chosen fields, which approximately 1000 cells per
section. Data were expressed as the percentage of BrdU-stained hepatocytes per total number of hepatocytes. Positive hepatocytes for BrdU
incorporation are stained in brown. (Original magnification x200) (B) PCNA expression was significantly higher in WT mice treated with anakinra at a
dose of 50mg/kg/d compared to untreated WT mice at 24 h after 70% hepatectomy. At a 10 times lower dose (5mg/kg/d), PCNA expression was not
different at 24 h in treated and untreated WT mice. At 48 h, the PCNA expression level was similar in all three groups of mice. Scale bars = 50 mm.
* = Statistical significance p,0.05. WT=wild type, PCNA=proliferating cell nuclear antigen, BrdU=bromodeoxyuridine.
doi:10.1371/journal.pone.0025442.g005
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higher in mice treated with anakinra compared to untreated mice
at 4 h post-hepatectomy (Figure 6B), this difference was not
statistically significant. Finally, IL-1b levels were similar between
the untreated and treated mice (Figure 6C). These data show that
treatment with anakinra leads to a decreased secretion of the pro-
inflammatory cytokine IL-6 early after partial hepatectomy.
Measurement of alanine aminotransferase (ALT). ALT
was analyzed on peripheral blood of WT mice treated with
anakinra (n=3) and compared to WT mice without treatment
(n=3). Our results showed that alanine aminotransferase increase
at 4h after partial hepatectomy and returned to normal levels after
72h. The levels of alanine aminotransferase of WT mice without
treatment was significantly higher at 24h after partial hepatectomy
compared to mice treated with anakinra (5 or 50mg/kg). For
treated mice, there was no difference for the protective effect of
anakinra between 5 and 50mg/kg (Figure 7).
Effect of anakinra on the proliferation of primary human
hepatocytes
In vitro, proliferation of primary human hepatocytes was
evaluated by analyzing PCNA expression by western blotting at
24 h, 48 h and 72 h after treatment with anakinra (10 mg/ml and
100 mg/ml). PCNA expression was significantly higher in primary
human hepatocytes treated with anakinra at 10 mg/ml and at
100 mg/ml in the first 24 h after treatment compared to primary
human hepatocytes without treatment (fold increase 2.060.4,
2.260.5 vs 1.0, respectively) (Figure 8A). After 48 h and 72 h of
anakinra treatment, PCNA expression level was similar between
untreated and treated human hepatocytes (Figure 8A). In
Figure 8B, our results showed that the cell viability was similar
for all culture conditions (n=3) (with or without anakinra) at
various time points.
Discussion
In the present study, we characterized the effects of IL-1ra gene
disruption and IL-1ra treatment on liver regeneration of mice after
partial hepatectomy. IL-1ra deficiency lead to a delay and a
decrease in liver regeneration analyzed by BrdU incorporation
and PCNA expression compared to WT mice. Peak of hepatocyte
proliferation was observed at 72 h post-hepatectomy in IL-1ra KO
mice compared to 48 h post-hepatectomy in WT mice and then
decreased until reaching basal level at 7 days after hepatectomy.
Figure 6. Cytokine profile during liver regeneration in WT mice treated by anakinra after hepatectomy. The cytokines IL-6, MCP-1 and
IL-1b were measured on peripheral blood of WT mice untreated or treated with two doses of anakinra (5mg/kg/d and 50mg/kg/d for 4 days) at 4 h,
24 h, 48 h and 72 h after partial hepatectomy. A) At 4 h post-hepatectomy, IL-6 levels increased significantly in the three groups of mice compared to
levels before hepatectomy. However, the levels of IL-6 were significantly higher in untreated mice than in WT mice treated with anakinra at 4 h post-
hepatectomy. However there was no difference between mice treated with 5mg/kg and those treated with 50mg/kg; B) the levels of MCP-1 were
higher but did not reach statistical significance in mice treated with anakinra compared to untreated mice at 4 h post-hepatectomy; C) There was no
difference in the levels of IL-1b between the three groups of mice. * = Statistical significance p,0.05. IL-6 = Interleukin-6, MCP-1 = monocyte
chemotactic protein-1, IL-1b = Interleukin-1b, WT = wild type.
doi:10.1371/journal.pone.0025442.g006
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observed that IL-1ra KO mice demonstrated higher serum levels
of IL-1b, IL-6 at 4 h and MCP-1 levels at 4 h and 24 h (in the
proliferation phase) compared to WT mice. Indeed, as shown by
several authors using various cell types including hepatic cells, IL-
1ra blocks the production of IL-1b, IL-6 and MCP-1
[14,15,27,28]. Increased MCP-1 secretion could also be related
to the increased levels of IL-1b observed in IL-1ra KO mice as this
cytokine has been reported to increase MCP-1 synthesis in non
hepatic cells [29,30] and stellate cells [31,32].
These increased levels of pro-inflammatory cytokines may
explain the delayed and reduced liver regeneration observed in IL-
1ra KO mice. Indeed, IL-1b has been previously shown to
antagonize hepatocyte proliferation [9,10,11]. Moreover, while
IL-6 is known to stimulate the priming phase of liver regeneration,
previous studies have shown that an overdose of IL-6 inhibits liver
regeneration and delays cell cycle progression after partial
hepatectomy [33,34,35,36]. Finally, CC chemokine family mem-
bers such as MCP-1 have been shown to modulate liver
inflammation [37] and to play a role in the ischaemia/perfusion
injury [38]. Although the mechanism of action of MCP-1 in the
liver inflammatory process is unclear, this cytokine may directly
cause impairment of hepatocyte proliferation. It is particularly
noteworthy that MCP-1 serum levels were highest in patients with
fulminant hepatic failure and fatal outcome compared to patients
with acute non-fulminant hepatitis and favourable outcome [39].
The next phase of liver regeneration includes activation of
tyrosine kinase receptor, c-met and epidermal growth factor (EGF)
ligands, which, in turn, activate expression of transcription factors
involved in liver regeneration. The main transcription factors
activated after partial hepatectomy are c-jun, C/EBPb and cAMP-
responsive element modulator (CREM) [40]. Studies in C/EBP-b
knockout mice revealed that this transcription factor was required
for both gluconeogenesis and cell proliferation during liver
regeneration [41]. As expected, C/EBP-b expression was
significantly increased in the early phase of liver regeneration in
WT mice and remained unchanged in IL-1ra KO mice after
partial hepatectomy suggesting that the transcription factor C/
EBP- b is modulated via IL-1ra.
Another important liver-specific immediate-early gene activated
during liver regeneration and implicated in the maintenance of
hepatocyte differentiation is the insulin-like growth factor binding
protein 1 (IGFBP-1) [42]. The role of IGFBP-1 in liver
regeneration is unknown but IGFBP-1 knockout mice showed a
reduced and delayed hepatocyte DNA replication after partial
hepatectomy [43]. While IGFBP-1 expression was significantly
increased in the early phase of liver regeneration in WT mice, a
very mild activation of IGFBP-1 gene was observed for IL-1ra
KO. Several studies showed a link between IGFBP-1, C/EBP-b
expression and IL-1 signalling pathway [43]. Thus, the decrease of
IGFBP-1 and C/EBP-b expression in IL-1ra KO may explain the
reduction and the delay of liver regeneration.
During liver regeneration, transition through S-phase requires
the synthesis of a group of proteins such as DNA polymerase a,c -
myc and cdc2 [44]. We observed that expression of early and
delayed genes and transcription factors were also altered in IL-1ra
KO mice after partial hepatectomy. Expression of the immediate
early C-MYC gene was not statistically different between WT and
IL-1ra KO mice, although C-MYC expression tended to be lower
in IL-1ra deficient mice. The lower increase in expression of
transcription factors and immediate early genes described above
may alter the hepatocyte cell cycle and delay the transition
through the S-phase.
Further progress through the cell cycle is dependent on
activation by growth factors including HGF. During the priming
phase (from 0 h to 20 h after hepatectomy) and proliferation phase
(from 20 h to 5 days), we observed a significant increase in IL-1ra
level and HGF in WT mice. These increased levels were observed
until 48 h post-hepatectomy (proliferation phase) and then
progressively decreased. These results are in accordance with
Molnar et al. demonstrating in vitro that HGF induces its anti-
inflammatory effects by upregulating the production of IL-1ra
Figure 7. Measurement of alanine aminotransferase. Alanine aminotransferase (ALT) was analyzed on peripheral blood of WT mice treated
with anakinra (n=3) compared to WT mice without treatment (n=3). Our results showed that alanine aminotransferase increase at 4h after partial
hepatectomy and returned to normal levels after 72h. The levels of alanine aminotransferase of WT mice without treatment was significantly higher at
24h after partial hepatectomy compared to mice treated with anakinra (5 or 50mg/kg). For treated mice, there was no difference for the protective
effect of anakinra between 5 and 50mg/kg. * = Statistical significance p,0.05. WT = wild type.
doi:10.1371/journal.pone.0025442.g007
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ability by induction of anti-inflammatory cytokines such as IL-1ra
[46,47]. HGF secretions were similar between WT and IL-1ra KO
mice after hepatectomy, but as IL-1ra was not synthesized in the
latter, HGF could not exert its regenerative ability.
Finally, reduced expression of transcription factors, immediate
early genes and growth factors described here were associated with
a delayed cell cycle transition of hepatocytes. The evaluation of
cell cycle protein expression performed by analyzing cyclin D1
expression demonstrated that the start and the peak of expression
was delayed in IL-1ra KO mice compared to WT mice. Because
cyclin D1 regulates the G1/S cell cycle transition, the delay of
cyclin D1 induction is likely also responsible for the delay and
decrease in hepatocyte proliferation in IL-1ra KO mice.
The presented data indicate a potential mechanism for IL-1ra
involvement in hepatocyte proliferation by promoting cell cycle
transition from G1 to S phase. This could be mediated by IL-1ra
released from hepatocytes to act upon the cell membrane IL-1
receptor [48]. Further, IL-1ra may act via an undefined
intracellular mechanism to increase transcription of cell cycle
proteins such as cyclin D1 in a similar way that it has been
proposed for IL-1a [49] .
Anakinra, a non glycosylated recombinant human IL-1ra, was
already used in various animal models of human diseases and also
in several human clinical trials of rheumatoid arthritis with relative
success [19,50].
We evaluated the liver regeneration in WT mice treated with
anakinra at 5mg/kg and at 50mg/kg after partial hepatectomy. Our
results showed that hepatocyte proliferation was significantly higher
only in animals treated with anakinra at 50mg/kg 24 h after partial
hepatectomy. Thisfindingcan be explained by the factthat an efficient
inhibition of IL-1 induced biological responses required injection of
100- to 1000-fold molar excess of IL-1ra. This might be due to the
differential affinity of IL-1 and IL-1ra for IL-1 receptor [51,52].
In our study, we showed that the treatment of WT mice with
anakinra at 5mg/kg and at 50mg/kg after partial hepatectomy
decreased levels of IL-6 but did not modify levels of IL-1b and of
MCP-1 (fig. 7). These results are in line with two others studies. In
a rat ischemia-reperfusion model, pre-treatment with IL-1ra gene
delivery into the liver has been shown to decrease serum levels of
IL-6 [17,18]. In Shinoda et al reported an improvement of survival
and a decrease of serum levels of IL-6 in a rat model of ALF
treated by a bioartificial liver device containing transfected
hepatocytes or by anakinra alone [14,15].
Figure 8. Evaluation of proliferation of primary human hepatocytes treated by anakinra in vitro studies. A) Primary human hepatocytes
were isolated and cultured for 24 h before treatment with anakinra (10 mg/ml and 100 mg/ml). After 24 h, 48 h and 72 h proteins were extracted and
whole cell lysats were subjected to western blotting. At 24 h, PCNA expression was significantly increased in hepatocytes treated with anakinra
compared to non-treated hepatocytes. This difference is not observed at the other time points. The results are expressed as a ratio of PCNA
expression by actin expression and are normalized in relation to none treated human hepatocytes. The quantification of bands of PCNA and actin
were performed by densitometry. B) To study the cell viability, we performed a crystal violet assay. Human hepatocytes were first seeded at 100,000
cells/well in 500 ml culture medium in 24-well plates with or without adjunction of anakinra at 10 and 100 microgr/ml for 24h and viability was tested
at 24, 48 and 72h. Our results showed that the cell viability was similar for all culture conditions (with or without anakinra) at various time points
(n=3). * = Statistical significance p,0.05. HH = primary human hepatocyte, PCNA = proliferating cell nuclear antigen.
doi:10.1371/journal.pone.0025442.g008
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of WT mice treated with anakinra compared to mice without
treatment. Our results showed that alanine aminotransferase
increase at 4h after partial hepatectomy and returned to normal
levels after 72h. The levels of alanine aminotransferase of WT
mice without treatment was significantly higher at 24h after partial
hepatectomy compared to mice treated with anakinra (5 or 50mg/
kg). For treated mice, there was no difference for the protective
effect of anakinra between 5 and 50mg/kg (Figure 7). These results
indicate that the anti-inflammatory effect prevented further liver
injury within the first 24 hours.
In vitro, we confirmed the proliferative effect of anakinra on
isolated human hepatocytes. Primary human hepatocytes treated
with anakinra showed a higher hepatocyte proliferation within the
first 24 h compared to untreated cells (Figure 8A). This positive
effect of IL-1ra may be related to its effects on cell proliferation as
suggested by several studies using endothelial cells, pancreatic b-
cells and hepatoyctes [4,5,53,54,55]. Indeed, Corsgrove et al.
reported a pro-proliferative role of IL-1ra on rat hepatocyte
proliferation when it was combined with TNF in vitro [56] . We
analyzed the cell viability of primary human hepatocytes treated
with anakinra and showed that the viability was similar for all
culture conditions (with or without anakinra) at various time points
(Figure 8B). These results suggest that the difference in cell
proliferation between the human hepatocytes cultured with and
without anakinra was not due to a difference of viability.
In conclusion, we provide evidence that liver regeneration is
transiently impaired IL-1ra KO mice after 70% hepatectomy.
Furthermore, decrease of pro-inflammatory cytokines (IL-6, MCP-
1 and IL-1b), differences in the timing or level of secretion of
cytokines (IL-6), of expression of cell cycle protein (cyclin D1) and
of expression of genes (IGFBP-1, C/EBPb, C-myc) that are
involved in priming the hepatocyte for entry into the cell cycle or
that regulate the G1/S checkpoint suggest that IL-1ra may
contribute and modulate hepatocyte proliferation in the early
phase of liver regeneration.
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